Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.

Transplantation · 2016 · PMC4683033 · PMID 26555945

Europe PMC DOI

hedged sentence

0.2096

closest p · 4.2× alpha

0.2096

boldest claim

The sentences

did not reach statistical significanceP = 0.2096not close (p > 0.1)

At study end, the OS rate in the ITT population was 68.4% in group A and 74.6% in group B (Figure 2 A, bottom), which did not reach statistical significance ( P = 0.2096, log-rank test; HR, 0.81; 95% CI, 0.58-1.13).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.